A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Study Purpose

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in subjects with resected advanced melanoma requiring adjuvant treatment with pembrolizumab.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - At least 18 years of age.
  • - Advanced Melanoma.
  • - Completely removed melanoma by surgery performed within 13 weeks of randomization.
  • - Adequate organ function.
  • - Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

Exclusion Criteria:

  • - Known history or evidence of ocular or uveal melanoma.
  • - Known history of hypersensitivity (grade ≥3) to pembrolizumab or its excipients.
  • - Known History of auto-immune disease.
  • - Received live vaccine ≤30 days before the first study treatment.
  • - Prior treatment with anti-PD-1 agents or agent against another stimulatory or co-inhibitory T cell receptor.
  • - Active autoimmune disease that has necessitated chronic systemic treatment within 2 years before the first study treatment.
Other protocol-defined inclusion/exclusion criteria apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06153238
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Sandoz
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Bosnia and Herzegovina, Brazil, France, Georgia, Germany, Italy, Korea, Republic of, Lithuania, Malaysia, Moldova, Republic of, Philippines, Romania, South Africa, Spain, Turkey, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Melanoma
Additional Details

Eligible subjects will be randomized in a 1:1:1 ratio to receive either GME751, Food and Drug Administration (FDA)-licensed pembrolizumab (Keytruda-US) or European Union (EU)-authorized pembrolizumab (Keytruda-EU). The maximum study duration for a participant will be approximately 28 weeks including screening. Treatment duration is 24 weeks (4 treatment cycles, each of 6 weeks duration). However, subject should discontinue study participation in case of disease recurrence, unacceptable toxicity or other reasons. Participants who are benefiting from treatment with pembrolizumab without signs of recurrence or unacceptable toxicity will be eligible for continued pembrolizumab treatment via most suitable option based on the respective country regulations.

Arms & Interventions

Arms

Experimental: GME751

Subjects will receive GME751 via intravenous (IV) infusion.

Active Comparator: Keytruda - EU

Subjects will receive Keytruda-EU via intravenous (IV) infusion.

Active Comparator: Keytruda - US

Subjects will receive Keytruda-US via intravenous (IV) infusion.

Interventions

Drug: - GME751

400 mg Q6W, i.v. infusion, over 24 weeks period

Drug: - Keytruda - EU

400 mg Q6W, i.v. infusion, over 24 weeks period

Drug: - Keytruda - US

400 mg Q6W, i.v. infusion, over 24 weeks period

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Sandoz Investigational Site, Orange, California

Status

Recruiting

Address

Sandoz Investigational Site

Orange, California, 92868

Sandoz Investigational Site, Clermont, Florida

Status

Recruiting

Address

Sandoz Investigational Site

Clermont, Florida, 34711

Sandoz Investigational Site, Orange City, Florida

Status

Recruiting

Address

Sandoz Investigational Site

Orange City, Florida, 32763

International Sites

Sandoz Investigational Site, Banja Luka, Bosnia and Herzegovina

Status

Recruiting

Address

Sandoz Investigational Site

Banja Luka, ,

Sandoz Investigational Site, Mostar, Bosnia and Herzegovina

Status

Recruiting

Address

Sandoz Investigational Site

Mostar, ,

Sandoz Investigational Site, Sarajevo, Bosnia and Herzegovina

Status

Recruiting

Address

Sandoz Investigational Site

Sarajevo, ,

Sandoz Investigational Site, Tuzla, Bosnia and Herzegovina

Status

Recruiting

Address

Sandoz Investigational Site

Tuzla, ,

Sandoz Investigational Site, Barretos, Brazil

Status

Recruiting

Address

Sandoz Investigational Site

Barretos, ,

Sandoz Investigational Site, Curitiba, Brazil

Status

Recruiting

Address

Sandoz Investigational Site

Curitiba, ,

Sandoz Investigational Site, Porto Alegre, Brazil

Status

Recruiting

Address

Sandoz Investigational Site

Porto Alegre, ,

Sandoz Investigational Site, Besançon, France

Status

Withdrawn

Address

Sandoz Investigational Site

Besançon, ,

Sandoz Investigational Site, Nantes, France

Status

Recruiting

Address

Sandoz Investigational Site

Nantes, ,

Sandoz Investigational Site, Batumi, Georgia

Status

Recruiting

Address

Sandoz Investigational Site

Batumi, ,

Sandoz Investigational Site, Tbilisi, Georgia

Status

Recruiting

Address

Sandoz Investigational Site

Tbilisi, ,

Sandoz Investigational Site, Mainz, Germany

Status

Recruiting

Address

Sandoz Investigational Site

Mainz, ,

Sandoz Investigational Site, Muenster, Germany

Status

Recruiting

Address

Sandoz Investigational Site

Muenster, ,

Sandoz Investigational Site, Tuebingen, Germany

Status

Recruiting

Address

Sandoz Investigational Site

Tuebingen, ,

Sandoz Investigational Site, Catanzaro, Italy

Status

Recruiting

Address

Sandoz Investigational Site

Catanzaro, ,

Sandoz Investigational Site, Rozzano, Italy

Status

Recruiting

Address

Sandoz Investigational Site

Rozzano, ,

Sandoz Investigational Site, Seoul, Korea, Republic of

Status

Recruiting

Address

Sandoz Investigational Site

Seoul, ,

Sandoz Investigational Site, Klaipeda, Lithuania

Status

Recruiting

Address

Sandoz Investigational Site

Klaipeda, ,

Sandoz Investigational Site, Vilnius, Lithuania

Status

Recruiting

Address

Sandoz Investigational Site

Vilnius, ,

Sandoz Investigational Site, George Town, Malaysia

Status

Recruiting

Address

Sandoz Investigational Site

George Town, ,

Sandoz Investigational Site, Johor Bahru, Malaysia

Status

Recruiting

Address

Sandoz Investigational Site

Johor Bahru, ,

Sandoz Investigational Site, Kuala Lumpur, Malaysia

Status

Recruiting

Address

Sandoz Investigational Site

Kuala Lumpur, ,

Sandoz Investigational Site, Kuching, Malaysia

Status

Recruiting

Address

Sandoz Investigational Site

Kuching, ,

Sandoz Investigational Site, Melaka, Malaysia

Status

Recruiting

Address

Sandoz Investigational Site

Melaka, ,

Sandoz Investigational Site, Putrajaya, Malaysia

Status

Recruiting

Address

Sandoz Investigational Site

Putrajaya, ,

Sandoz Investigational Site, Chisinau, Moldova, Republic of

Status

Recruiting

Address

Sandoz Investigational Site

Chisinau, ,

Sandoz Investigational Site, Bacolod, Philippines

Status

Recruiting

Address

Sandoz Investigational Site

Bacolod, ,

Sandoz Investigational Site, Bucharest, Romania

Status

Recruiting

Address

Sandoz Investigational Site

Bucharest, ,

Sandoz Investigational Site, Cluj-Napoca, Romania

Status

Recruiting

Address

Sandoz Investigational Site

Cluj-Napoca, ,

Sandoz Investigational Site, Johannesburg, South Africa

Status

Recruiting

Address

Sandoz Investigational Site

Johannesburg, ,

Sandoz Investigational Site, Phoenix, South Africa

Status

Recruiting

Address

Sandoz Investigational Site

Phoenix, ,

Sandoz Investigational Site, Barcelona, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Barcelona, ,

Sandoz Investigational Site, Cáceres, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Cáceres, ,

Sandoz Investigational Site, Madrid, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Madrid, ,

Sandoz Investigational Site, Murcia, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Murcia, ,

Sandoz Investigational Site, Santiago De Compostela, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Santiago De Compostela, ,

Sandoz Investigational Site, Sevilla, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Sevilla, ,

Sandoz Investigational Site, Valencia, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Valencia, ,

Sandoz Investigational Site, Zaragoza, Spain

Status

Recruiting

Address

Sandoz Investigational Site

Zaragoza, ,

Sandoz Investigational Site, Ankara, Turkey

Status

Recruiting

Address

Sandoz Investigational Site

Ankara, ,

Stay Informed & Connected